RemeGen’s Telitacicept OLE Data Selected for Oral Presentation at AANEM 2025

RemeGen (688331.SH/09995.HK) announced that 48-week open-label extension (OLE) results of telitacicept (RC18, ThaiAi®) will be presented at the AANEM 2025 Annual Meeting.

The event runs October 29 to November 1, 2025 at the Hilton San Francisco Union Square, California, USA.

Oral Presentation Details

• Title: Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study.
• Session: MGFA, organized by the MGFA Medical and Scientific Advisory Committee.
• Timing: October 29, 2025, at 10:50 AM PST (October 30, 1:50 AM Beijing time).

This session will feature leading clinical and scientific experts discussing the latest peer-reviewed research in myasthenia gravis.

Earlier Phase III Data Showed Strong Efficacy

At the 2025 AAN Annual Meeting in March, RemeGen presented 24-week Phase III data:

• 98.1% of patients achieved ≥3-point improvement in MG-ADL score.
• 87% achieved ≥5-point improvement in QMG score.
• Among Phase III drugs for gMG, telitacicept showed the highest MG-ADL response rate.

The upcoming 48-week data are expected to reinforce its potential as a best-in-class therapy for generalized myasthenia gravis.

Out-Licensing and Global Development

In June 2025, RemeGen out-licensed telitacicept to Vor Bio (Nasdaq: VOR).

Vor Bio is advancing a global multicenter Phase III trial across the United States, Europe, South America, and Asia-Pacific, with recruitment progressing smoothly.

About Telitacicept

Telitacicept is the world’s first BLyS/APRIL dual-target fusion protein.

• Developed independently by RemeGen.
• Blocks BLyS and APRIL binding to B-cell receptors.
• Prevents abnormal B-cell differentiation and maturation.
• Treats autoimmune diseases by modulating the immune system.

It has been approved in China for:

• Systemic lupus erythematosus (SLE).
• Rheumatoid arthritis (RA).
• Generalized myasthenia gravis (gMG).

About Vor Bio

Vor Bio is a clinical-stage biotech company developing treatments for autoimmune diseases.

The company focuses on Phase III development and commercialization of telitacicept to address unmet needs in autoimmune conditions.

About Generalized Myasthenia Gravis (gMG)

gMG is a rare, chronic autoimmune disease that disrupts nerve-muscle communication.

• Symptoms include muscle weakness affecting mobility, vision, swallowing, and breathing.
• Driven by autoantibodies against AChR or MuSK, impairing neuromuscular transmission.
• Current treatments leave many patients with refractory symptoms or severe side effects.

The unmet need is significant:

• 90,000 patients in the U.S.
• 140,000 in Europe
• 29,000 in Japan

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!